Back

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

European Heart Journal

29 April 2020
Organised by: Logo
Read full article
ESC Journals HEART FAILURE Chronic Heart Failure BASIC SCIENCE

Contributors

Milton Packer
Milton Packer

Author

Baylor University Medical Center Dallas , United States of America

You may be interested in
thumbnail
Congress Presentation
SGLT2i in heart failure with reduced ejection fraction: benefits in real life?
22 May 2023
thumbnail
Webinar
Nonsteroidal MRAs and heart failure: interpretation and impact on practice - which patients should be receiving MRAs?
21 July 2025
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources